Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Amicus Therapeutics Inc FOLD

Amicus Therapeutics, Inc. is a biotechnology company, which is focused on discovering, developing, and delivering novel medicines for rare diseases. Its two marketed therapies are Galafold, the first oral monotherapy for people living with Fabry disease who have amenable genetic variants, and Pombiliti + Opfolda, a novel treatment designed to improve uptake of active enzyme into key disease... see more

NDAQ:FOLD - Post Discussion

Amicus Therapeutics Inc > Buy Recommendation Issued On FOLD By Bank of America Securit
View:
Post by whytestocks on Oct 17, 2024 1:32pm

Buy Recommendation Issued On FOLD By Bank of America Securit

Just In: $FOLD Buy Recommendation Issued On FOLD By Bank of America Securities2024-10-17 13:15:05 ET Bank of America Securities analyst issues BUY recommendation for FOLD on October 17, 2024 11:06AM ET. The previous analyst recommendation was Buy. FOLD was trading at $12.0311 at issue of the analyst recommendation. The overall analyst consensus : ...FOLD - Buy Recommendation Issued On FOLD By Bank of America Securities
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities